Is rifampin resistance a reliable predictive marker of multidrug-resistant tuberculosis in China: a meta-analysis of findings

Drug-resistant tuberculosis (TB), including rifampicin (RIF)-resistant TB (RR-TB) and multidrug-resistant tuberculosis (MDR-TB, with resistance to at least isoniazid and rifampicin), is becoming a threat to public health worldwide.1,2 An estimated 558,000 MDR/RR-TB cases emerged in 2017, of which approximately half of MDR-TB cases were reported in India, China and Russia.1 Due to limited availability of quality-assured laboratory resources in TB-endemic countries, confirmed cases of MDR-TB likely account for only a small proportion of actual cases.
Source: Journal of Infection - Category: Infectious Diseases Authors: Source Type: research